831 Serum Biomarkers Are Associated With Endoscopic and Clinical Outcomes in Crohn’s Disease Patients Receiving Vedolizumab Therapy

INTRODUCTION: Vedolizumab is a selective monoclonal antibody directed against a4b7 integrin on lymphocytes and is safe and effective for the induction and maintenance of remission in Crohn’s disease. Serum biomarkers are needed to help guide therapy and predict patient outcomes. This study evaluated biomarker concentrations and patient outcomes during vedolizumab treatment. METHODS: Serum was collected from patients with Crohn’s disease...